Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Control Release ; 368: 329-343, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38431094

RESUMO

Rheumatoid arthritis (RA) is a prevalent autoimmune disease characterized by excessive inflammation in the joints. Glucocorticoid drugs are used clinically to manage RA symptoms, while their dosage and duration need to be tightly controlled due to severe adverse effects. Using dexamethasone (DEX) as a model drug, we explored here whether peptide-guided delivery could increase the safety and therapeutic index of glucocorticoids for RA treatment. Using multiple murine RA models such as collagen-induced arthritis (CIA), we found that CRV, a macrophage-targeting peptide, can selectively home to the inflammatory synovium of RA joints upon intravenous injection. The expression of the CRV receptor, retinoid X receptor beta (RXRB), was also elevated in the inflammatory synovium, likely being the basis of CRV targeting. CRV-conjugated DEX increased the accumulation of DEX in the inflamed synovium but not in healthy organs of CIA mice. Therefore, CRV-DEX demonstrated a stronger efficacy to suppress synovial inflammation and alleviate cartilage/bone destruction. Meanwhile, CRV conjugation reduced immune-related adverse effects of DEX even after a long-term use. Last, we found that RXRB expression was significantly elevated in human patient samples, demonstrating the potential of clinical translation. Taken together, we provide a novel, peptide-targeted strategy to improve the therapeutic efficacy and safety of glucocorticoids for RA treatment.


Assuntos
Artrite Experimental , Artrite Reumatoide , Humanos , Camundongos , Animais , Glucocorticoides/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Inflamação , Artrite Experimental/tratamento farmacológico , Peptídeos/uso terapêutico , Índice Terapêutico
2.
Sci Rep ; 6: 29110, 2016 06 30.
Artigo em Inglês | MEDLINE | ID: mdl-27357559

RESUMO

Superparamagnetic iron oxide nanoparticles (SPIONs) as a contrast agent have been widely used in magnetic resonance imaging for tumor diagnosis and theranostics. However, there has been safety concern of SPIONs with cirrhosis related to excess iron-induced oxidative stress. In this study, the impact of iron overload by SPIONs was assessed on a mouse cirrhosis model. A single dose of SPION injection at 0.5 or 5 mg Fe/kg in the cirrhosis group induced a septic shock response at 24 h with elevated serum levels of liver and kidney function markers and extended impacts over 14 days including high levels of serum cholesterols and persistent low serum iron level. In contrast, full restoration of liver functions was found in the normal group with the same dosages over time. Analysis with PCR array of the toxicity pathways revealed the high dose of SPIONs induced significant expression changes of a distinct subset of genes in the cirrhosis liver. All these results suggested that excess iron of the high dose of SPIONs might be a risk factor for cirrhosis because of the marked impacts of elevated lipid metabolism, disruption of iron homeostasis and possibly, aggravated loss of liver functions.


Assuntos
Cirrose Hepática/fisiopatologia , Fígado/efeitos dos fármacos , Nanopartículas de Magnetita/efeitos adversos , Estresse Oxidativo/efeitos dos fármacos , Animais , Meios de Contraste/efeitos adversos , Meios de Contraste/uso terapêutico , Modelos Animais de Doenças , Humanos , Sobrecarga de Ferro/induzido quimicamente , Sobrecarga de Ferro/fisiopatologia , Fígado/fisiopatologia , Cirrose Hepática/induzido quimicamente , Imageamento por Ressonância Magnética , Nanopartículas de Magnetita/uso terapêutico , Camundongos , Nanomedicina Teranóstica , Distribuição Tecidual/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA